Objective: To investigate the gene mutation in adult patients with B-ALL and its influence on clinical prognosis.
Methods: Clinical data of 226 adult patients with B-ALL were retrospectively analyzed in the period from August 2011 to February 2018. The incidence of gene mutation in all patients were detected, and the influence of mutation gene on clinical prognosis were estimated. Cox regression model were used to evaluate the independent prognostic factors.
Results: 208 (92.04%) of 226 patients showed gene mutations, and the median mutation number was 2 (0-8). Among them, 54 cases (23.89%) showed 14 or more mutations. The top five mutation types of all patients were SF1, FAT1, MPL, PTPNII and N-RAS respectively. The median OS and median RFS times of 226 patients were 27.0 (5.5-84.0) months and 22.5 (0-81.0) months respectively. The OS and RFS times of Ph B-ALL patients with JAK1 and JAK2 mutations were significantly shorter than those of patients without JAK2 mutations (P<0.05). The OS and RFS times of Ph B-ALL patients with abnormal JAK-STAT signaling pathway were significantly shorter than those of patients without abnormal JAK-STAT signaling pathway (P<0.05). The OS and RFS times of Ph B-ALL patients with epigenetic related signaling pathway mutations were significantly shorter than those of patients without epigenetic related signaling pathway mutations (P<0.05). Cox regression model multivariate analysis showed that WBC level was the independent influencing factor for total survival time and relapse-free survival time in adult B-ALL patients (P<0.05). With or without JAK2 mutation and WBC level were the independent influencing factor for overall survival time and relapse-free survival time of adult Ph B-ALL patients (P<0.05).
Conclusion: Gene mutations are common in all adult B-ALL patients, and the clinical prognosis of patients with JAK and epigenetics-related signaling pathway mutations is worsen, while the WBC level closely relates to the clinical prognosis of the patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.06.013 | DOI Listing |
Ophthalmic Plast Reconstr Surg
October 2024
Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, U.S.A.
Probl Radiac Med Radiobiol
December 2024
State Institution «National Research Center of Radiation Medicine, Hematology and Oncology of the National Academy of Medical Sciences of Ukraine», 53 Yuriia Illienka Str., Kyiv, 04050, Ukraine.
Objective: To determine the structure of abnormalities of bone tissue and substantiate the management tactics inacute lymphoblastic leukemia (ALL) pediatric patients and in children with no oncohematological disorders, livingin radiologically contaminated territories (RCT).
Materials And Methods: Children (n = 220) living in RCT were the study participants i.e.
Front Oncol
December 2024
Department of Hepatobiliary Surgery of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Preface And Importance: Burkitt's lymphoma (BL) is a relatively rare post-transplant lymphoproliferative disorder (PTLD), and there is currently limited research on the occurrence of BL following adult liver transplantation.
Case Introduction: We report a 45-year-old male who developed BL that rapidly progressed at seven years after left liver transplantation. The patient eventually abandoned treatment due to severe clinical complications.
J Pediatr Hematol Oncol
December 2024
Division of Paediatric Cardiology.
Background: Burkitt's lymphoma (BL) is the most common subtype of non-Hodgkin lymphoma in children, typically presenting with extranodal masses in areas such as the abdomen, face, and neck. Cardiac involvement in BL is extremely rare, especially in pediatric patients, and has significant implications for diagnosis, management, and prognosis.
Case Presentation: A 6-year-old male patient with Burkitt's lymphoma, presenting with an uncommon infiltration of the interatrial septum, is described.
BMC Nephrol
December 2024
Department of Pharmacy, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.
Background: Although Proton pump inhibitors (PPIs) were mostly prescribed for gastrointestinal (GI) disease widely, there were numerous studies about PPIs and adverse renal outcome. Most evidence was to evaluate the risk of PPIs in patients with normal renal function and in the absence of the moderate to advanced chronic kidney disease (CKD). This study focuses on the accelerated progression of renal function following proton pump inhibitors (PPIs) use, and the increased risks of acute kidney injury (AKI) among moderate to advanced CKD (pre-ESRD) patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!